Reviva Pharmaceuticals Holdings, Inc.: Form 10-Q for the period ended Mar 31, 2024
Filed with the SEC on May 14, 2024 and accepted by EDGAR at May 14, 2024, 08:13 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2024-01-01 to 2024-03-31 | $5.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-01-01 to 2024-03-31 | −$7.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-01-01 to 2024-03-31 | $3.5k | us-gaap:InterestExpense |
| Income tax | 3 months2024-01-01 to 2024-03-31 | $7.4k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-01-01 to 2024-03-31 | −$7.4m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2024-01-01 to 2024-03-31 | −$0.25 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 3 months2024-01-01 to 2024-03-31 | −$11.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2024-03-31 | $12.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Total assets | At period end2024-03-31 | $13.5m | us-gaap:Assets |
| Current liabilities | At period end2024-03-31 | $14.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-03-31 | $14.8m | us-gaap:Liabilities |
| Short-term borrowings | At period end2024-03-31 | $332.0k | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2024-03-31 | −$1.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-24-016366. Last ingested by Listed: Oct 29, 2026, 16:33 ET. Listed shows no prices and gives no investment advice.